Symmetry Investments’s Biogen BIIB Stock Holding History

Symmetry Investments’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,070	Closed	-$1.23M	–	150
2024 Q4	$1.23M	Buy	+8,070	New	+$1.36M	0.06%	116

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Symmetry Investments's BIIB Position: Q1 2025 in Review

Symmetry Investments sold out of Biogen (BIIB) in Q1 2025, closing a stake of 8,070 shares — an estimated $1.23M sold.

Symmetry Investments first reported a position in BIIB in Q4 2024 and held it in 1 quarter. The position peaked at $1.23M in Q4 2024. 880 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

Symmetry Investments reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
Symmetry Investments sold 8,070 Biogen shares in Q1 2025, an estimated $1.23M.
Symmetry Investments first reported a position in Biogen in Q4 2024 and held it in 1 quarter.
Symmetry Investments's Biogen position peaked at $1.23M in Q4 2024.
880 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Symmetry Investments's 13F filing for Q1 2025, filed 15 May 2025.